Table of contents
Nguyen Injury Lawyer is actively investigating potential lawsuits for individuals who have experienced NAION, gastroparesis, or other gastrointestinal issues, such as bowel obstruction or cyclic vomiting syndrome, after using Ozempic. Ozempic, a well-known brand name for semaglutide, is a prescription medication primarily used to manage type 2 diabetes. It has also gained popularity as a weight loss aid. Recent research suggests that Ozempic, particularly when taken in higher doses, may lead to gastroparesis.
Until recently, Ozempic’s warning label did not adequately inform patients and healthcare providers about these potential risks. If you have suffered harm after taking Ozempic, you may be entitled to financial compensation through a product liability lawsuit.
Lawsuits concerning Ozempic, Rybelsus, Wegovy, Trulicity, and Mounjaro have been consolidated into a multidistrict litigation (MDL) class action. While NAION lawsuits are becoming more common, vision loss cases are being handled separately from the MDL, as detailed in the updates below. This page offers the latest news and updates on the Ozempic litigation, along with insights into the potential settlement values of these cases.
If you believe you have a case, contact Nguyen Injury Lawyer today at XXX-XXX-XXXX, or visit our website at https://www.nguyeninjurylawyer.com to reach out to us online for a free consultation.
Ozempic Lawsuit Updates
Our attorneys at Nguyen Injury Lawyer are dedicated to providing you with the most current information and news regarding this litigation. Please check back regularly for updates.
March 15, 2026 – Wegovy and NAION Risk
A significant new safety concern has emerged regarding GLP-1 drugs. A recent study indicates that Wegovy may pose a considerably higher risk of vision loss compared to Ozempic, despite both containing the same active ingredient, semaglutide. The key difference appears to be the dosage. Wegovy is prescribed at higher doses, and the study found that patients taking it were approximately five times more likely to develop ischemic optic neuropathy, also known as an “eye stroke.”
Previous studies have already suggested that Ozempic and Wegovy users face roughly double the risk of NAION compared to individuals taking other diabetes medications. However, this new analysis intensifies the concern. Researchers reviewed over 30 million FDA adverse event reports and discovered that semaglutide drugs, specifically, were the only drugs strongly linked to optic nerve injury. Wegovy exhibited the most pronounced safety signal.
Importantly, the study did not find the same level of risk with Mounjaro or Zepbound. This suggests that the issue is not class-wide, but rather specific to semaglutide, and that dosage plays a critical role.
March 4, 2026 – FDA Cites Misleading Advertising by Novo Nordisk
The FDA recently issued a warning to Novo Nordisk regarding a television advertisement for Ozempic that contained false or misleading claims. The ad implied that Ozempic was superior to other GLP-1 diabetes drugs and suggested that most patients with type 2 diabetes were suitable candidates for the medication. The FDA stated that these claims were not supported by evidence. The agency also noted that the ad failed to adequately present important risk information and gave Novo Nordisk 15 working days to respond and correct the violations.
While the FDA’s warning does not directly address safety risks like NAION, the eye condition at the center of Ozempic vision loss lawsuits, it is still relevant. In pharmaceutical litigation, regulatory findings of misleading advertising can bolster arguments that the manufacturer promoted the drug more aggressively than justified by scientific evidence. Plaintiffs in NAION cases argue that Novo Nordisk expanded Ozempic’s use without fully disclosing potential risks, making scrutiny of the company’s marketing practices a significant aspect of the overall case.
March 2, 2026 – NAION Warning
In the U.K., the Medicines and Healthcare products Regulatory Agency has issued a safety update warning that semaglutide, marketed as Wegovy, Ozempic, and Rybelsus, may be linked to a serious eye condition causing sudden vision loss in rare cases.
The regulator suggests that semaglutide may be associated with non-arteritic anterior ischemic optic neuropathy (NAION), which affects the optic nerve and typically results in sudden, painless vision loss in one eye. Patients experiencing sudden or rapidly worsening eyesight while taking semaglutide are advised to seek immediate medical attention.
February 16, 2026 – Thyroid Cancer
A new study concludes that GLP-1 drugs like Wegovy, Mounjaro, Ozempic, and Zepbound do not appear to increase the risk of thyroid cancer in humans. Although these medications carry an FDA boxed warning based on rodent studies showing C-cell tumors, researchers found no reliable human data indicating an increased risk of thyroid cancer or accelerated tumor growth.
This finding is significant in the context of GLP-1 litigation. Currently, over 3,000 product liability lawsuits are pending, primarily focusing on gastroparesis and vision injuries such as non-arteritic anterior ischemic optic neuropathy (NAION), consolidated in two MDLs in the Eastern District of Pennsylvania before Judge Karen Marston.
It’s important to avoid alleging that a blockbuster drug causes every serious medical event reported after its use. These drugs provide benefits to some individuals. When new data contradicts a thyroid cancer theory, it’s best to acknowledge it and shift focus. Plaintiffs are better served by concentrating on injury categories where the scientific evidence is stronger and more consistent, such as NAION vision loss. These claims are supported by growing adverse event data, mechanistic plausibility, and a developing body of peer-reviewed literature.
February 16, 2026 – Status Conference Update
During the February 10, 2026, status conference, the Court and counsel addressed key administrative and case management issues in the MDL.
First, the parties provided a comprehensive docket update, including current MDL case counts, the number of newly filed short-form complaints, and the status of Plaintiff Fact Sheet submissions and compliance. The discussion focused on overall inventory growth, any deficiencies in PFS production, and whether additional case management steps are needed to keep discovery on track.
Second, the Court received updates on related state court litigation in Delaware, Indiana, and New Jersey. Counsel outlined the procedural posture of those cases, any upcoming trial settings or dispositive motions, and coordination issues between the MDL and parallel state proceedings.
Third, the parties addressed the management of mixed-injury cases, specifically the Brown, Lee, Marsh, Morris, and Ralph matters. These cases involve overlapping or multiple injury theories that raise case administration and discovery sequencing questions. The judge discussed how those cases will proceed within the MDL framework. Finally, the court considered the pending motion in Daigle seeking to convert a dismissal, with counsel outlining their respective positions on whether the prior dismissal should be modified and how that would affect the case going forward.
January 17, 2026 – Our 2026 Prediction
We at Nguyen Injury Lawyer predict that NAION cases will have significant value. Gastroparesis cases will be valuable for victims who have suffered long-term, permanent injuries. Gastroparesis cases where the victim did not suffer significantly or for an extended period are unlikely to be worth as much.
January 6, 2026 – 3,097 Total MDL Cases
As of January 2026, the GLP-1 weight loss drug MDL includes 3,063 pending cases.
More Ozempic Lawsuit Updates 👈
December 9, 2025 – Update on MDL Cases
With the rapid increase in the use of Ozempic and other GLP-1-based weight loss drugs, the related class action MDL continues to grow. In November alone, 27 new cases were added, bringing the total number of filings to 2,947. This upward trend reflects the widespread use of these medications and the increasing number of patients alleging undisclosed or insufficiently warned-about side effects.
September 30, 2025 – MDL Case Count Update
The Ozempic / GLP-1 MDL now has 2,914 pending cases, an increase of 800 new cases since August 1. This indicates approximately 200 new cases are being added to this MDL each month.
September 30, 2025 – New Lawsuit Yesterday
In a new lawsuit filed yesterday, a woman from Cabazon, California, claims she suffered severe and potentially permanent gastrointestinal injuries after using Wegovy.
The plaintiff, who began taking Wegovy in May 2023, alleges that she developed ileus, a blockage in the small intestine, followed by a diagnosis of gastroparesis. She asserts that these injuries caused significant pain, vomiting, and required medical intervention, ultimately leading her to discontinue the drug.
The complaint accuses the defendants of failing to adequately warn consumers and physicians about the risks of serious gastrointestinal side effects, including conditions requiring emergency care or hospitalization. The plaintiff further contends that Novo Nordisk aggressively marketed Wegovy as a “miracle” weight loss drug while downplaying its risks and misleading consumers about the drug’s long-term efficacy and safety.
September 21, 2025 – Shift of Focus to NAION
Plaintiffs have faced challenges in proving that gastroparesis was directly caused or worsened by Ozempic, rather than being an existing complication of underlying diabetes.
The focus of this litigation has since shifted to vision loss and a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION).
The narrative for these cases is more straightforward and compelling. In August 2024, the European Medicines Agency ordered updated warning labels for Ozempic and related drugs to include vision loss and NAION risk, which plaintiffs’ lawyers can use as regulatory validation. NAION also presents the advantage (from a litigation standpoint) of being sudden and severe, often resulting in permanent partial or total vision loss in one eye. This clarifies damages and simplifies the argument for causation, especially when there is no pre-existing diabetes-related eye disease. NAION offers a clearer narrative for juries, and our attorneys at Nguyen Injury Lawyer are now focusing on these cases.
September 11, 2025 – NAION MDL Sought (by Lilly)
Eli Lilly has filed a motion to centralize all federal lawsuits alleging vision loss from GLP-1 receptor agonist drugs, specifically claims involving non-arteritic anterior ischemic optic neuropathy (NAION).
The motion seeks either the creation of a new MDL, termed “GLP-1 RAs Products Liability Litigation (No. II),” or the consolidation of these NAION cases into the existing MDL No. 3094, which currently handles gastrointestinal injury claims involving the same class of drugs. These include Lilly’s Mounjaro and Trulicity, as well as Novo Nordisk’s Ozempic and Wegovy.
Lilly has explicitly requested that the cases be assigned to Judge Karen Marston in the Eastern District of Pennsylvania, where she already presides over MDL 3094. The company argues that her familiarity with the relevant science, regulatory history, and case management structure makes her the most logical and efficient choice to oversee the expanding litigation.
The assertive nature of this motion is notable. Defendants typically resist MDL treatment because consolidation can galvanize the plaintiff bar and accelerate discovery pressure. Lilly’s active pursuit of centralization reveals a clear strategy: they want Judge Marston to handle these claims.
Updates on Ozempic and Wegovy Litigation
The motion highlights what are being called “combination cases” that allege both GI and NAION injuries, which Lilly contends require coordinated pretrial proceedings. However, Nguyen Injury Lawyer believes this is a tactic to influence the court, suggesting Lilly perceives Judge Marston as sympathetic to the defense.
Regardless, the NAION docket in New Jersey, which handles cases from plaintiffs across the country, is expected to continue its growth, whether or not a new MDL is established.
September 6, 2025 – Types of Ozempic Claims We Are Handling
Based on Judge Marston’s recent order, Nguyen Injury Lawyer is now accepting two types of claims:
- Vision injuries (NAION)
- Gastroparesis confirmed by a gastric emptying study (scintigraphy, breath test, or WMC)
September 5, 2025 – Raw Materials Used in GLP-1 Drugs
The FDA recently announced a new “green list” of foreign manufacturers authorized to supply raw materials for compounded versions of GLP-1 drugs like Wegovy and Mounjaro.
This action seeks to control the influx of unsafe or counterfeit active pharmaceutical ingredients used by compounders, while still allowing some compounding under strict quality standards. While over three dozen overseas suppliers were listed, their names were not disclosed, and imports from non-listed companies may be detained.
Both Lilly and Novo Nordisk experienced stock drops following this announcement.
September 1, 2025: Wegovy Approved for Fatty Liver Disease
The FDA has approved Wegovy (semaglutide) for treating metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease in adults with moderate to advanced fibrosis. This is the first GLP-1 drug approved for MASH.
August 15, 2025: Significant New Ruling
U.S. District Judge Karen Spencer Marston has issued two significant rulings that will impact the future of the GLP-1 receptor agonist MDL, which involves over 2,000 cases against Novo Nordisk and Eli Lilly.
In her recent order, the judge addressed a series of Daubert motions, ruling that plaintiffs’ gastroparesis claims must be supported by objective medical testing. According to Judge Marston, “any Plaintiff claiming to suffer (or have suffered) from gastroparesis, must show that their diagnosis is based on a properly performed gastric emptying study.” Nguyen Injury Lawyer argues that while this standard may narrow the scope of viable claims, it also compels defendants to confront plaintiffs who have definitive diagnostic evidence.
This ruling confirms that the litigation is ongoing. The companies attempted to dismiss twelve of the seventeen counts in the master complaint, arguing that statements about their drugs being “safe and effective” were non-actionable puffery and that design defect theories were federally preempted.
Judge Marston partially agreed, dismissing design defect claims and striking vague allegations about fraudulent omissions in general marketing. However, she rejected the puffery defense, noting that plaintiffs had identified specific safety and efficacy representations, often promoted by paid scientists and celebrities, that went beyond simple marketing. These representations, she found, “are sufficient to survive dismissal at this early stage of the litigation.” Crucially, the court held that omissions from the drugs’ labels, including the absence of gastroparesis warnings, were pled with enough specificity to proceed.
For victims, these rulings have mixed implications. While claims of stomach paralysis now require a gastric emptying study or equivalent test, potentially excluding individuals whose diagnoses were based solely on clinical observations, the core argument remains: Novo and Lilly aggressively marketed GLP-1 drugs for weight loss while concealing known risks, generating billions in revenue. Warranty and labeling claims remain valid, and the court has not dismissed state law negligence and warranty counts at this point. Ultimately, victims who can provide objective proof of their injuries still have a clear path to trial, and Novo and Lilly will face discovery on allegations that they knowingly minimized life-altering side effects in their pursuit of market dominance.
August 14, 2025 – New Jersey NAION Class Action Gaining Momentum
Novo Nordisk may soon face coordinated mass tort proceedings in New Jersey state court regarding claims that its popular weight loss drugs, Ozempic and Wegovy, caused permanent vision loss.
Over 30 plaintiffs have requested multicounty litigation designation, an increase of nine since our last report on June 17. The plaintiffs allege that the drugs caused them to develop non-arteritic anterior ischemic optic neuropathy (NAION), a serious and irreversible condition. The proposed venue is Middlesex County, where the cases are currently distributed among eight judges and involve plaintiffs from 13 states.
While often referred to as a class action, it is technically a multicounty litigation, a coordinated mass tort structure that centralizes pretrial proceedings without consolidating the cases for trial. Each plaintiff retains an individual claim, but discovery, expert challenges, and motions practice are streamlined across the docket. This approach aims for efficiency and often provides plaintiffs with greater structural leverage, particularly in early bellwether trials or global settlement discussions.
Nguyen Injury Lawyer notes a growing trend in mass torts: law firms are increasingly choosing state courts to pursue complex drug injury claims, avoiding the procedural bottlenecks and evidentiary restrictions common in many federal MDLs. The current trajectory of the Ozempic MDL is one that our attorneys seek to avoid.
July 15, 2025 – Texas Woman Sues Over Sudden Blindness After Ozempic Use
A recent lawsuit filed in Travis County, Texas, alleges that a 52-year-old woman experienced sudden and irreversible blindness after using Ozempic for only six months. The complaint states that she developed NAION in one eye and lost 90 percent of her vision within a single day. Her attorneys claim that Novo Nordisk disregarded early warning signs in clinical trials and failed to provide adequate warnings to physicians or patients. The lawsuit also references recent studies suggesting that semaglutide may impair optic nerve blood flow.
This case is one of several new cases in state courts outside the MDL, highlighting a growing trend: vision loss plaintiffs are increasingly willing to forgo federal consolidation in favor of faster-moving, high-visibility trials at the state level. Nguyen Injury Lawyer believes this case is particularly strong if these injuries can be directly linked to Ozempic.
June 24, 2025 – Ozempic and Wegovy Linked to Increased Risk of Vision Loss
A new study in JAMA Ophthalmology adds to the growing list of concerns about Ozempic and Wegovy, specifically regarding vision loss.
Researchers at the University of Toronto found that patients taking semaglutide, the active ingredient in both drugs, were twice as likely to develop neovascular age-related macular degeneration (nAMD). This condition gradually destroys central vision and can lead to permanent impairment.
The study examined nearly 140,000 patients with type 2 diabetes from 2020 to 2023. While the absolute risk was small, with just over two in 1,000 semaglutide users developing nAMD compared to one in 1,000 non-users, the increase was statistically significant. Researchers controlled for other known risk factors, including kidney function, smoking, and the use of insulin and metformin.
The biological plausibility of these findings is significant. GLP-1 drugs like Ozempic alter vascular and inflammatory pathways, mechanisms directly involved in macular degeneration. This information should be carefully considered by both doctors and patients.
Ozempic was not initially marketed as a weight loss solution, but it became one. The public embraced it before scientific understanding fully caught up. Now that evidence is emerging, first about stomach paralysis and now about vision problems, companies like Novo Nordisk must answer for both what they disclosed and what they failed to investigate.
June 17, 2025 – NAION Claims Are Gaining Traction
Twenty-one New Jersey plaintiffs who claim they suffered permanent vision loss after taking Ozempic or Wegovy are seeking to consolidate their lawsuits into a multicounty litigation against Novo Nordisk. They are asking New Jersey state courts to coordinate the increasing number of cases involving non-arteritic anterior ischemic optic neuropathy (NAION), a rare and irreversible eye condition. These plaintiffs argue that centralization would streamline discovery, reduce inconsistent rulings, and improve litigation management as filings continue to rise, mirroring the arguments that led to the gastroparesis MDL.
Notably, NAION claims are now attracting more attention from lawyers than the earlier wave of gastroparesis lawsuits. While stomach paralysis cases initially drove the Ozempic litigation, the vision-loss allegations are generating significant interest due to the severity of the injuries.
Permanent blindness, especially when it occurs suddenly and without warning, represents a particularly serious injury that is more likely to drive individual lawsuits, media coverage, and potential jury trials.
As scientific studies continue to explore a possible causal link between GLP-1 receptor agonists and optic nerve damage, these cases are expected to remain a primary focus.
June 10, 2025 – NAION Warning
Momentum is building for the FDA to take action regarding the potential vision risks associated with Ozempic. Several ophthalmologists and public health advocates are urging the agency to require a black box warning on semaglutide drugs, including Ozempic, Wegovy, and Rybelsus, due to growing evidence linking them to nonarteritic anterior ischemic optic neuropathy (NAION).
This push follows recent reports in JAMA Ophthalmology and a Danish registry study suggesting a statistically significant association between semaglutide use and sudden vision loss events. Attorneys involved in the New Jersey multicounty litigation are amplifying the call for regulatory change, arguing that Novo Nordisk has long been aware of this potential risk but has failed to update its labeling accordingly.
A black box warning would be a significant development, reshaping physician prescribing practices and potentially opening the door to new failure-to-warn liability claims. For plaintiffs’ lawyers, it would provide strong evidence that the dangers of NAION were both foreseeable and preventable.
Nguyen Injury Lawyer anticipates growing pressure, particularly as more independent case reports emerge and media coverage highlights the life-altering nature of these injuries. This issue is evolving beyond a litigation story and rapidly becoming a public health concern.
June 2, 2025 – Early Defense Strategy in Vision Loss Cases
Novo Nordisk is already indicating its defense strategy for the NAION lawsuits: attributing the injuries to underlying health conditions. In recent filings, the company has suggested that diabetes, hypertension, and high cholesterol, common among Ozempic users, are known risk factors for optic nerve damage and vision loss, implying that any injury suffered by plaintiffs may not be related to semaglutide exposure.
If you have suffered vision loss or gastroparesis after taking Ozempic or Wegovy, contact Nguyen Injury Lawyer at XXX-XXX-XXXX or visit our contact page for a free consultation. You can also visit our website at https://www.nguyeninjurylawyer.com for more information.
Defense Strategy and Emerging Scientific Concerns
Pharmaceutical defense attorneys often attempt to portray conditions as multifactorial, aiming to diminish the drug’s role. However, this can be a risky strategy when presented to a jury. Attorneys for the plaintiffs will argue that Novo Nordisk had a responsibility to provide warnings, even if the drug only marginally increased the baseline risk. This is especially critical considering that diabetic patients are already more susceptible to ocular damage and would exercise greater caution if fully informed of the risks.
This defense also disregards the growing scientific agreement that NAION events are occurring at a higher rate than expected in patients using semaglutide. Some of the most severe cases are appearing in individuals with no prior significant eye problems. Should the litigation proceed to expert testimony and case-specific discovery, juries may be unsympathetic to a company that downplays such catastrophic injuries as mere coincidence.
These early indications suggest that the NAION litigation will not simply mirror the gastroparesis MDL but could develop into a distinct legal battleground. This new battleground would feature unique scientific inquiries, different plaintiff demographics, and a greater potential for significant verdicts.
May 19, 2025 – Ozempic Vision Loss Lawsuits Filed Over NAION Side Effect
The Ozempic litigation is growing, with multiple lawsuits filed against Novo Nordisk by patients who developed non-arteritic anterior ischemic optic neuropathy (NAION), a serious and potentially irreversible eye condition that can lead to blindness after using Ozempic.
These new Ozempic lawsuits claim that Novo Nordisk neglected to warn patients and healthcare providers about the risk of NAION, despite evidence from clinical trials, post-marketing surveillance, and adverse event reports. These cases are particularly concerning because the current Ozempic label does not include any warning about vision loss or NAION, despite scientific literature and real-world reports suggesting a connection between semaglutide (the active ingredient in Ozempic) and optic nerve damage.
The Nguyen Injury Lawyer team anticipates that these vision loss claims will increase. Similar lawsuits involving Wegovy and Rybelsus, two other semaglutide drugs manufactured by Novo Nordisk, are also being developed. All three medications belong to the GLP-1 receptor agonist drug class and share similar pharmacological profiles.
From a legal perspective, the argument is clear: patients were never given the opportunity to make an informed decision, and many would not have chosen to use Ozempic had they been properly warned. Plaintiffs’ lawyers are highlighting the company’s documented aggressive marketing tactics, including off-label promotion of Ozempic for weight loss, as further evidence that patient safety was secondary to profit.
For attorneys already monitoring Ozempic stomach paralysis or gallbladder injury claims, these vision loss lawsuits introduce a new and severe injury theory. NAION lawsuits may result in significantly higher settlement amounts due to the life-altering nature of blindness and the complete absence of warnings.
April 21, 2025 – New Study
A CDC-supported study published in the Annals of Internal Medicine found that semaglutide-related emergency room visits occurred an estimated 25,000 times between 2022 and 2023, with most visits occurring in 2023. The majority of these visits involved semaglutide alone, almost always in injectable form, and were triggered by serious gastrointestinal issues or hypoglycemia. Many cases required hospitalization.
Defendants will likely downplay these findings by characterizing the overall rate of visits as “rare,” but this term does not accurately reflect the severity of the outcomes. Nearly 40 percent of hypoglycemia cases and 15 percent of gastrointestinal cases resulted in hospital stays. These are not minor side effects; they are serious medical events that represent risks that must be clearly communicated to patients and doctors.
February 26, 2025 – New NAION Study
A study recently published in JAMA Ophthalmology investigated the potential link between semaglutide and non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause sudden vision loss.
The research analyzed data from 37.1 million adults with type 2 diabetes, including over 810,000 new users of semaglutide. The findings indicated an increase in the relative incidence of NAION among semaglutide users compared to those not exposed to the drug. Specifically, the incidence rate was 14.5 cases per 100,000 person-years among semaglutide users.
While this condition does not occur frequently, Nguyen Injury Lawyer believes there should be a warning about the risk of this serious eye problem so that patients can decide whether to accept the risk. It is our firm belief that a warning is necessary.
The authors of this study also recommend that healthcare providers consider this increased risk when prescribing Ozempic, Rybelsus, and Wegovy and discuss it with patients as part of a comprehensive benefit-risk assessment.
January 28, 2025 – New Study, More Concern
A recent study published in JAMA Otolaryngology–Head & Neck Surgery has added another layer of concern to the growing Novo Nordisk Ozempic lawsuits and the broader litigation over GLP-1 receptor agonists.
The study analyzed data from over 350,000 adults with type 2 diabetes and found that patients initiating GLP-1RA therapy—including drugs like Ozempic and Mounjaro—had a significantly increased risk of being diagnosed with thyroid cancer within the first year of use compared to those prescribed other diabetes medications.
Like most individual studies, this study does not definitively prove causation. It is possible that the increased diagnosis rate is due to increased medical surveillance rather than the drug directly causing cancer. However, the findings raise further concerns about the potential risks of GLP-1 medications. Nguyen Injury Lawyer believes there is too much evidence of potential harm associated with these drugs to ignore these new side effects.
January 22, 2025 – New Study Raises Additional Concerns About Ozempic
A new January 2025 study has raised additional concerns about Ozempic and similar GLP-1 receptor agonists (GLP-1RAs). While these medications are widely promoted as groundbreaking treatments for diabetes and obesity, this latest research highlights a troubling reality: Ozempic may not be as safe as advertised. The study reveals a mixed bag of health outcomes, with real benefits coupled with significant risks that raise serious questions about the drug’s overall safety profile.
While GLP-1RAs like Ozempic may reduce the risks of dementia, heart disease, and some infections, they are also associated with severe and often life-altering complications. The study found increased risks of gastrointestinal disorders, kidney stones, arthritis, fainting, and even drug-induced pancreatitis in patients using these medications. This adds to the growing body of evidence suggesting that Ozempic may not be as safe as advertised. Patients who trusted these medications to improve their health are now dealing with unexpected and painful consequences—consequences that drug manufacturers either overlooked or failed to adequately warn about. This is another reminder that marketing, early success, and media attention do not tell the whole story.
Does this mean Ozempic is a harmful drug and should be recalled? Not necessarily. However, Nguyen Injury Lawyer believes drug manufacturers should be required to warn of known risks.
November 13, 2024 – New Lawsuit
In a new lawsuit filed as part of the national MDL for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Philadelphia, a Tennessee woman alleges that Novo Nordisk’s drugs, Ozempic and Wegovy, caused her to develop severe, chronic gastrointestinal injuries, including gastroparesis.
The plaintiff was prescribed Ozempic in 2022 to manage diabetes and weight. She soon began to experience persistent vomiting, nausea, and extreme stomach discomfort. After ongoing symptoms, she underwent a gastric emptying study in early 2023, a diagnostic test widely regarded as the gold standard for diagnosing delayed gastric emptying or gastroparesis, which confirmed her condition. This objective test result is likely to be significant evidence in the litigation.
Her lawsuit alleges that Novo Nordisk failed to adequately warn users and healthcare providers of the drugs’ severe gastrointestinal risks, including gastroparesis, stomach paralysis, and intestinal blockages—risks the plaintiff argues the company either knew or should have known based on prior clinical studies and adverse event data. She also alleges Novo Nordisk downplayed these risks in its marketing, portraying the drugs as safe, effective, and essential for weight management, while omitting critical information about the drugs’ serious side effects and the likelihood of weight regain if discontinued.
November 4, 2024 – Gastric Emptying Studies Grow in Importance
The MDL judge appears to have questions about whether plaintiffs can prove that gastroparesis is caused by Ozempic or even whether an individual plaintiff can prove they have gastroparesis. Consequently, there is a renewed emphasis on how to definitively establish whether a patient has gastroparesis, amid concerns that a doctor’s diagnosis alone may not suffice.
This has led to a new focus on gastric emptying studies as a key element of proof in the GLP-1 agonist litigation. These studies, which measure the rate at which food leaves the stomach, are considered the most objective way to identify delayed gastric emptying, a primary symptom and clinical hallmark of gastroparesis.
As the litigation progresses, gastric emptying studies will increasingly be viewed as the key to substantiating claims that drugs like Ozempic may alter gastrointestinal motility. Presenting gastric emptying study results in court provides scientific support and helps distinguish true cases of gastroparesis from other digestive issues.
November 1, 2024 – Scheduling Order
The path forward is as follows:
| Deadline | Description |
|---|---|
| July 2, 2025 | Deadline for fact discovery |
| July 16, 2025 | Deadline for Plaintiffs to serve expert reports |
| August 13, 2025 | Deadline for Defendants to serve expert reports |
| August 22, 2025 | Deadline for Plaintiffs to serve rebuttal expert reports |
| October 10, 2025 | Deadline for all parties to complete expert depositions |
| October 27, 2025 | Deadline for submission of motions to exclude expert opinions under Rule 702 and initial briefs |
| October 29, 2025 | Deadline for submission of summary judgment motions and initial briefs |
| December 3, 2025 | Deadline for submission of briefs in opposition to Rule 702 motions |
| December 16, 2025 | Deadline for submission of briefs in opposition to summary judgment motions |
| December 17, 2025 | Deadline for submission of reply briefs in support of Rule 702 motions |
| January 16, 2026 | Deadline for submission of reply briefs in support of summary judgment motions |
At Nguyen Injury Lawyer, we are committed to providing you with honest assessments. This schedule indicates a lengthy legal process. All of the above is merely to prepare for individual lawsuits and conduct further discovery on the defendants if we are successful. Ozempic lawyers are already tightening their criteria, recognizing the long-term nature of this litigation. This will be a marathon, not a sprint.
Ozempic
Ozempic (generically known as semaglutide) is a prescription medication used to manage type 2 diabetes. It belongs to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists. GLP-1 is a hormone released in response to food intake that helps regulate blood sugar levels.
There is also evidence that Ozempic can induce weight loss in individuals with obesity, even those without diabetes. While Ozempic is approved for the management of type-2 diabetes, doctors have also prescribed it to treat obesity and aid in weight management.
Ozempic is manufactured by Novo Nordisk.
If you have experienced adverse side effects from Ozempic, contact Nguyen Injury Lawyer at XXX-XXX-XXXX for a free consultation. You can also visit our website at https://www.nguyeninjurylawyer.com or reach out through our contact page at https://www.nguyeninjurylawyer.com/contact.
Novo Nordisk developed Ozempic in 2012, and the FDA approved it for the U.S. market in December 2017. The drug primarily addresses diabetes. In 2021, the FDA approved a higher-dose version of Ozempic under the brand name Wegovy.
Ozempic and similar GLP-1 drugs stimulate insulin production after meals. GLP-1, a naturally occurring peptide, regulates blood sugar. GLP-1 agonists, like Ozempic, mimic this peptide to treat type 2 diabetes, effectively reducing blood sugar levels and slowing digestion to maintain normal glucose levels. Ozempic is administered weekly via injection, ranging from 0.25 mg to 1 mg.
Clinical trials revealed Ozempic’s weight-loss effects, leading to semaglutide’s approval in higher doses as Wegovy for chronic weight management.
While Ozempic helps many patients, questions arise about whether the manufacturer adequately warned about all potential risks. Nguyen Injury Lawyer is focusing on claims related to NAION and gastroparesis, prioritizing NAION cases.
The Challenges of Gastroparesis
Gastroparesis involves impaired stomach muscle function, hindering proper food movement through the digestive system. This condition disrupts digestion, causing nausea, vomiting (sometimes of undigested food), abdominal pain, bloating, dehydration, early satiety, acid reflux, fluctuating blood sugar, appetite loss, weight loss, nutrient deficiency, and a diminished quality of life.
Unfortunately, there is currently no cure for gastroparesis.
Imagine experiencing hunger, only to be met with pain, nausea, and vomiting upon eating. Gastroparesis sufferers endure a relentless cycle of discomfort, transforming the basic need to eat into a constant struggle. Each meal becomes a calculated risk, often followed by regret. The psychological impact is as significant as the physical symptoms. Constant worry about flare-ups, anxiety about eating in public, and the stress of managing a safe and nourishing diet can be overwhelming.
The pain and discomfort of gastroparesis are chronic, impacting every aspect of life and casting a shadow over daily activities and social interactions. Relief is often temporary, requiring sufferers to navigate various treatments and dietary adjustments to find some semblance of normalcy.
Gastroparesis is often misunderstood or overlooked, especially by those unfamiliar with its effects, leading to isolation for sufferers. Its symptoms are non-specific, resembling conditions like functional dyspepsia, irritable bowel syndrome, or peptic ulcer disease, which can lead to misdiagnosis or failure to diagnose the condition.
As an “invisible” illness, gastroparesis is often disregarded by family and friends, making empathy difficult to find. This can compound the emotional and physical burden for those affected.
The misery of gastroparesis stems not only from physical symptoms but also from its impact on life’s simple pleasures, such as enjoying a meal without fear or pain. It demands constant vigilance and adaptation, testing the resilience of those affected.
The Need for Proper Warnings
It is frustrating to learn that the medication taken to improve one condition may have led to another, such as cholecystitis or gastroparesis. Proper warnings are essential to provide context for these risks, potentially sparing individuals from this cycle of pain and despair. This is a central issue in Ozempic lawsuits.
Drug manufacturers have a duty to fully disclose the risks associated with their products, allowing patients to make informed decisions about their healthcare. This is where lawsuits become necessary to hold manufacturers accountable.
NAION and Ozempic
In 2024, Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) emerged as a potential side effect of Ozempic. NAION involves blocked blood flow to the optic nerve, leading to sudden, sometimes irreversible vision loss.
While typically linked to risk factors like high blood pressure, diabetes, and elevated cholesterol, NAION can also occur unexpectedly due to the eye’s structural characteristics.
The link between Ozempic and NAION is not definitively proven; however, emerging studies suggest a connection. Research indicates that rapid fluctuations in blood glucose levels, common with diabetes medications like Ozempic, may adversely affect blood flow to the optic nerve, triggering NAION in susceptible individuals.
Nguyen Injury Lawyer is actively investigating these cases. Given the severity of NAION and its potential link to Ozempic, our attorneys believe that claims related to this issue could lead to substantial settlements, reflecting the life-altering impact of sudden vision loss. We are prepared to pursue these claims and hold responsible parties accountable.
Why NAION Claims Stand Apart
Unlike gastroparesis, NAION causes sudden and often permanent vision loss. This makes these claims easier to substantiate, as the injuries are evident, severe, and not easily confused with pre-existing conditions. These cases are more likely to result in higher settlement values.
Estimating Potential Ozempic Lawsuit Settlement Amounts
Estimating potential settlement values for new product liability cases is challenging, especially with Ozempic gastroparesis lawsuits. The strength of scientific evidence in these cases is a major variable. However, victims want to know potential payouts.
Based on assumptions about causation evidence, our attorneys estimate that a successful Ozempic lawsuit could have a settlement value range of $400,000 to $700,000 for “top tier” cases involving severe gastroparesis or death.
Less severe cases with injuries that resolve quickly will likely result in much lower payouts. Serious, permanent injury cases may yield significant value.
Practical Factors Influencing Ozempic Settlements
The financial dynamics of the pharmaceutical market suggest significant potential payouts in Ozempic litigation. Manufacturers generate substantial profits from Ozempic, Rybelsus, Wegovy, Trulicity, and Mounjaro, enabling them to handle extensive settlement costs.
Drug companies typically prefer to prolong litigation and are less concerned about adverse publicity. However, the substantial profits from these drugs may change this calculus. These companies may prefer settling claims quickly to protect profits and avoid the public relations disaster of a verdict and the scrutiny that adverse verdicts could bring.
Defendants might offer substantial settlements to resolve litigation quickly and mitigate negative publicity, maintaining the brand’s market position and avoiding additional harmful evidence that could lead to higher compensation claims or punitive damages.
The expectation is that defendants will issue significant compensation to claimants sooner rather than later to circumvent reputational damage and financial unpredictability associated with jury verdicts.
New Ozempic Warning
On September 28, 2023, the FDA added a new warning to the Ozempic label about the potential for increased risk of ileus, a blockage that prevents food or liquid from passing through the colon.
The new warning states:
Ileus: Ileus is a serious but rare side effect reported in patients taking Ozempic. Ileus can cause abdominal pain, nausea, vomiting, and constipation. If you experience any of these symptoms, contact your healthcare provider immediately.
The FDA recommends that healthcare providers monitor patients taking Ozempic for signs and symptoms of ileus and consider discontinuing Ozempic if ileus is suspected.
These developments underscore that the risks of Ozempic are still being determined.
Key Allegation
Every Ozempic lawsuit centers on the claim that Novo Nordisk failed to warn patients and doctors about the serious risk of gastroparesis and vision loss, leaving patients unaware of dangers that could have changed their decisions to use the drug.
The Focus of Every Ozempic Lawsuit Is the Failure to Warn
Every Ozempic lawsuit asserts the key claim that Novo Nordisk failed to provide adequate warnings about the risk of developing gastroparesis as a side effect of the drug.
While the Ozempic label mentions common adverse reactions like nausea, vomiting, diarrhea, abdominal pain, and constipation, it does not link these symptoms to gastroparesis or include them in the “Warnings and Precautions” section. The label mentions delayed gastric emptying in the context of drug interactions, describing a minor delay as part of the drug’s mechanism but does not explicitly state gastroparesis as a risk or potential chronic condition resulting from Ozempic use.
If you or a loved one has suffered due to complications from Ozempic, contact Nguyen Injury Lawyer at XXX-XXX-XXXX or through our website at https://www.nguyeninjurylawyer.com. You can also reach us through our contact page at https://www.nguyeninjurylawyer.com/contact.
Failure to Warn & Negligence
Novo Nordisk’s promotional materials, including their main website, do not mention the risk of gastroparesis in the “Important Safety Information” section. These materials also highlight changes in labeling over time, such as the removal of specific guidance on side effects from the “Patient Counseling Information” section, which may lead doctors to misinterpret symptoms like vomiting as minor or temporary.
Attorneys for Ozempic victims argue that Novo Nordisk knew or should have known about the potential link between Ozempic and gastroparesis, based on clinical studies, case reports, and medical literature. This is the central point of these lawsuits: the company allegedly failed to provide adequate warnings about this risk, leading to a lack of awareness in the medical community and affecting prescribing decisions. Nguyen Injury Lawyer is committed to holding them accountable.
It’s important to remember that the risk isn’t limited to Ozempic. Ozempic is a GLP-1 receptor agonist (GLP-1RA), and the risk of gastroparesis is common across the GLP-1RA class, which includes medications like tirzepatide, exenatide, liraglutide, albiglutide, dulaglutide, and lixisenatide. Published research on the association between gastroparesis and any GLP-1RA, not just Ozempic, should have alerted manufacturers to the need for warnings about this risk to patients and prescribing physicians.
Ozempic lawsuits argue that if the risks of gastroparesis had been adequately disclosed, it would have influenced the physician’s decision to prescribe Ozempic or to monitor for symptoms of gastroparesis more closely. Why wasn’t the risk disclosed? There could be many reasons, but it often comes down to money. More warnings equal fewer sales, which equals less profit. It’s as simple as that.
NAION Warning Case
In June 2025, European regulators added non-arteritic anterior ischemic optic neuropathy (NAION) as a very rare side effect on the Ozempic label. NAION is a serious eye condition that can cause sudden, permanent vision loss when blood flow to the optic nerve is disrupted.
The updated warning instructs patients to stop taking Ozempic immediately if they notice sudden changes in vision and to seek urgent medical care. Doctors in Europe are also being advised to discuss this risk with patients before prescribing semaglutide drugs such as Ozempic, Wegovy, or Rybelsus.
In the United States, the FDA has not yet added a specific NAION warning to the Ozempic label, though vision problems are mentioned more generally. This gap highlights a recurring concern: drugs like Ozempic are widely prescribed, but the full scope of their risks is still being uncovered. The recognition of NAION in Europe shows that safety questions remain and that regulators are still working to define the true risks of this medication.
Ozempic Multidistrict Litigation (MDL)
In February 2024, the MDL panel certified an Ozempic class action lawsuit. A Multidistrict Litigation (MDL) can potentially speed up the settlement process in lawsuits like the Ozempic case in two important ways that may lead to earlier Ozempic settlements:
Streamlined Proceedings
MDLs consolidate similar cases to streamline the legal process. By bringing numerous similar lawsuits into a single court, MDLs help reduce duplicative discovery, avoid conflicting rulings across courts, and increase the efficiency of the legal process. This consolidation can lead to quicker settlements because it creates pressure on the defendants to resolve many cases at once rather than dealing with each case individually over a prolonged period.
Higher Negotiation Leverage
In an MDL, the large number of cases consolidated together increases the plaintiffs’ leverage in settlement negotiations. This can encourage the defendant, in this case, Novo Nordisk, to settle to avoid the risk of facing a potentially large, cumulative judgment across many individual cases. Settlements in an MDL can offer compensation to claimants more quickly than individual lawsuits, which might take years to resolve. Ozempic settlement amounts are unlikely to be one-size-fits-all. If these claims are successful, Ozempic settlement payouts will vary depending on the severity of the side effects and the evidence supporting the plaintiffs’ claims.
Our lawyers sometimes refer to the Ozempic MDL (multidistrict litigation) as a class action lawsuit because that is what people call it (and, frankly, how they search it), but it is important to understand that these two legal mechanisms are distinct.
A class action lawsuit involves a group of plaintiffs who have suffered similar harm from the same defendant, and their cases are combined into a single lawsuit. This allows the group to be represented collectively by a member of the class, and any judgment or settlement applies to all class members. In a class action, the court must certify the class, establishing that the claims are sufficiently similar and that the representative parties will protect the interests of the class. You might see some classic Ozempic class actions filed in this litigation that include consumer claims for people who may not be injured.
On the other hand, an MDL consolidates individual Ozempic lawsuits with similar claims into a single court for pretrial proceedings, streamlining the process and making it more efficient. Each plaintiff in an MDL maintains their individual lawsuit, and their case is transferred back to its original court for trial if it does not settle during the MDL process. The primary goal of an MDL is to handle complex cases involving many plaintiffs and common factual issues more efficiently.
In the context of the Ozempic MDL, multiple individual cases related to the drug are consolidated for pretrial procedures. This allows for coordinated discovery and judicial efficiency but retains the individuality of each plaintiff’s claim. Unlike a class action, the outcomes in an MDL can vary for each plaintiff based on the specifics of their case.
What You Need to Know
If you developed gastroparesis or vision loss after taking Ozempic, Wegovy, or another GLP-1 drug, you may qualify for compensation. Lawsuits are already consolidated in federal and state courts, and deadlines may apply. Contact Nguyen Injury Lawyer today at XXX-XXX-XXXX for a free consultation, or visit our website at https://www.nguyeninjurylawyer.com or our contact page at https://www.nguyeninjurylawyer.com/contact.
Estimated Settlement Amounts
Estimating the potential settlement value of new product liability cases like this is almost impossible to do with any real accuracy. That is particularly true with the Ozempic gastroparesis lawsuits because they are very new. At this point, we don’t know how the scientific evidence behind these cases will hold up in court. That is a major variable in any defective drug case.
Still, victims want to know how much the Ozempic lawsuit will pay out. So what our lawyers can do, however, is provide an educated guess as to the possible settlement compensation payout range of Ozempic cases based on various assumptions about the causation evidence. Based on these significant assumptions, our attorneys believe that a successful Ozempic lawsuit could have a settlement value range of $200,000 to $500,000. This is the settlement value estimate for the “top tier” Ozempic cases, which would be those in which the plaintiff suffered severe gastroparesis or death.
But that is the best cases. The average Ozempic gastroparesis lawsuit will likely be much lower. Many cases may involve temporary injuries, hospital stays, or less severe complications. Those types of claims may be valued at $50,000 to $150,000, depending on the duration and impact of the condition. Of course, this assumes the MDL judge allows the gastroparesis cases to go forward. The reality is that a lot of lawyers have their doubts about this.
Some involve injuries that these drugs cause heal relatively quickly, and those cases will likely not see settlement payouts close to the larger figures. However, cases involving severe and permanent injuries may have significant value.
NAION Settlements
The most serious potential cases are the NAION lawsuits. In these cases, we are talking about sudden and permanent vision loss. Blindness in one or both eyes dramatically affects every aspect of life and usually leads to high settlement amounts when you can prove the defendant is responsible. Based on comparable drug injury cases, NAION-related Ozempic claims could reach $500,000 to $1 million or more, with bilateral blindness probably exceeding those figures. Nguyen Injury Lawyer is ready to fight for maximum compensation in these devastating cases. Call us at XXX-XXX-XXXX to discuss your options.
While no outcome is guaranteed, the tiered structure is clear. Lesser injuries will see modest payouts. Severe gastroparesis could reach the mid six figures. Permanent vision loss from NAION, however, is the type of catastrophic injury that commands the largest settlements in litigation of this kind.
Settlement Factors
The financial dynamics of the pharmaceutical market suggest significant potential payouts in the Ozempic-related litigation. These defendants are getting ridiculous profits from Ozempic, Rybelsus, Wegovy, Trulicity, and Mounjaro. These companies are in a position to handle extensive settlement costs without crippling their financial standing.
Drug companies typically like to prolong litigation as long as possible. They also do not care as much as you would think about besmirching the name of the company with adverse publicity of big verdicts against them. But this is different – they are worried about the drug’s reputation and their ability to sell more of it.
It is the profits these drugs are bringing in that may change the calculus. It may make it more likely that these companies will prefer settling claims out of court more quickly to protect their profits and avoid the public relations disaster of a verdict and the additional scrutiny that adverse verdicts on these drugs could bring.
The thinking is that these defendants might opt to offer substantial settlement payouts to quickly resolve the litigation and mitigate any negative publicity that could arise during a trial. Such a strategy not only helps maintain the brand’s market position but also potentially avoids the exposure of additional harmful evidence that could lead to even higher compensation claims or punitive damages.
The expectation/hope is that defendants will issue significant compensation to claimants sooner rather than later to circumvent the reputational damage and financial unpredictability associated with jury verdicts.
Weight Loss vs. Diabetes
We think injury lawsuits for patients taking Ozempic and related drugs for diabetes will receive real compensation if the claims are viable. Still, settlement amounts for Ozempic in weight loss cases may be higher than those for diabetes claims due to several factors.
First, the use of Ozempic for weight loss can involve a different patient demographic, potentially including younger individuals who may experience longer-term or more severe impacts from side effects, thereby increasing the perceived damages. Younger patients generally get higher settlement payouts than older patients in mass tort lawsuits.
Secondly, the expectations and marketing surrounding weight loss medications can create a higher perceived duty of care from pharmaceutical companies to disclose potential risks, which, if not adequately communicated, could lead to greater liability and thus higher settlements. The thinking is that weight loss is far more optional than diabetes, so failure to warn those patients is somehow worse. Jurors may view the failure to warn of side effects in a medication used for lifestyle or cosmetic reasons as more egregious than one used for managing a chronic health condition like diabetes, potentially leading to not only a greater chance of winning a failure to warn claim, but also a large punitive damages award. If you have been harmed, contact Nguyen Injury Lawyer for a free consultation at XXX-XXX-XXXX or through our website.
Causation Issues in Ozempic Cases
In Ozempic cases involving weight loss patients, establishing a direct link between the medication and adverse effects may be more straightforward compared to cases involving diabetic patients. This is because weight loss patients may not have the same underlying health issues as those with diabetes, making it easier to attribute certain side effects directly to the medication rather than pre-existing conditions. Defense attorneys are aware that juries often seek reasons to blame the patient. Skilled legal representation can mitigate this issue to some extent. Nevertheless, this perceived clearer causation can strengthen claims and potentially influence settlement amounts.
Projected Settlement Timeline for Ozempic Lawsuits
The timeline for settling Ozempic lawsuits, including those involving gastroparesis or NAION claims, remains uncertain. The litigation is still in its early stages, and case-specific discovery has not yet commenced. The Ozempic MDL is currently progressing through pretrial proceedings, with a primary focus on establishing general causation of the severe gastrointestinal risks associated with GLP-1 receptor agonists. Our attorneys do not anticipate any early Ozempic settlements or a large-scale resolution for several years. While this may not be the desired news, Nguyen Injury Lawyer believes in providing honest and realistic assessments.
Mass tort litigation is inherently unpredictable. As the Ozempic class action lawsuit advances, factors such as bellwether trials—early test cases designed to gauge jury reactions—will play a significant role in shaping potential settlement payouts. However, these milestones are still years away. In the meantime, individuals affected by Ozempic should stay informed as more lawsuits are filed, and hope that legal strategies continue to develop effectively to hold manufacturers accountable.
Consult with an Ozempic Attorney
If you are considering an Ozempic gastroparesis lawsuit, contact Nguyen Injury Lawyer today for a free consultation. You can reach us at XXX-XXX-XXXX or through our online contact page at https://www.nguyeninjurylawyer.com/contact. Our attorneys are here to help you understand your legal options.